Release Details

Webcast Alert: Isis Pharmaceuticals Discusses its New ISIS 301012 Phase 2 Clinical Data Presented at the DALM Symposium

October 1, 2007

CARLSBAD, Calif., Oct 01, 2007 /PRNewswire-FirstCall via COMTEX News Network/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) announces the following webcast:

    What:      New ISIS 301012 Phase 2 Clinical Data Presented at DALM

    When:      Monday, October 8, 2007, at 8:00 a.m. ET / 5:00 a.m. PT

    Where:     http://www.isispharm.com

    How:       Live on the Internet.  Simply log onto our web site listed
               above.

    Contacts:  Kristina Lemonidis
               Associate Director, Investor Relations
               (760) 603-2490

               Amy Blackley, Ph.D.
               Manager, Corporate Communications
               (760) 603-2772

If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at http://www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for a wide variety of diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000(TM) Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,500 issued patents worldwide. Additional information about Isis is available at http://www.isispharm.com.

SOURCE Isis Pharmaceuticals, Inc.

http://www.isispharm.com

News Provided by COMTEX